Ipsos Healthcare Extends Molecular Diagnostics Portfolio into Japan & Australia

Tuesday, March 11, 2014

New York, NY – Ipsos Healthcare’s Molecular Diagnostics (MDx) Portfolio has arrived in Japan and Australia. The MDx Monitors – already running in the USA and 5EU – reveal the drivers and barriers within the MDx landscape, as well as their impact on diagnosis, management and treatment. Currently, the monitors focus on oncology, with other therapy areas to be rolled out in the upcoming months.

The new Japanese Oncology MDx Monitor covers the MDx market in breast cancer, gastric cancer and lung cancer, gathering data from 160 physicians, including: general surgeons; GI internists; GI surgeons; respiratory surgeons; respiratory internists; and pathologists. Full results are available now. The Australia Oncology MDx Monitor, which launched in February, covers the MDx market in lung cancer and melanoma, with data collected from a mix of oncologists and pathologists.

By combining patient and test level data with perceptual data (including respondent awareness of, and attitudes towards, current and future MDx and CDx tests) the MDx Monitors provide a unique understanding of the link between perceptions and testing behaviour. Subscribers can understand the decision-making process and logistics; barriers to testing; timing of CDx testing; IVD and LDT market shares; impact of testing on drug shares; uptake of new methodologies; and requirements for reimbursement and payer restrictions.

Pieter De Richter, who heads up Ipsos Healthcare’s Molecular Diagnostics Monitors, said:

"The Japanese and Australian MDx Monitors enable pharma companies, biotechs, and MDx test manufacturers in these markets to gain unprecedented insight into the various factors shaping the complex Oncology MDx/CDx market. Both countries have unique differences that set them aside from the US and EU5, and being able to fully understand the complexities of molecular testing at a country-specific level will be of great benefit to companies looking to expand or fine-tune their MDx/CDx strategies in either of these important global markets."

For more information on this news release please contact:

Pieter De Richter
Head of MDx Portfolio
Ipsos Healthcare
646.313.7717
pieter.derichter@ipsos.com

Joanna Butcher
Marketing Director, Syndicated Services
Ipsos Healthcare
+44 7818 422117
joanna.butcher@ipsos.com

About Ipsos Healthcare’s Global Therapy Monitors

Ipsos Healthcare’s Global Therapy Monitors comprise the industry’s largest portfolio of syndicated patient chart audit data. The suite of global studies tracks usage of treatments across 20+ disease areas, including Metabolics, Oncology, Virology, Autoimmune, Cardiovascular and more. Together, they encompass 4000 physicians reporting on 200,000 patients in 35 markets worldwide. Subscribers to the Global Therapy Monitors can track product usage and maintain a comprehensive understanding of their ever-evolving markets.

About Ipsos Healthcare

Ipsos Healthcare is a global specialized practice focusing on research in the pharmaceutical, bio-tech and medical device markets. It is also a leading provider of global syndicated patient chart studies in 35 markets. Operating in over 40 countries, the team of 500 healthcare market research experts, marketers and client-side brand-builders focuses on delivering outcome-oriented research for its clients. Drawing from a broad range of qualitative and quantitative techniques, Ipsos Healthcare offers custom and syndicated research programmes to evaluate the motivations, experiences, interactions and influences of stakeholders forming the multi-customer markets that increasingly drive business success in the healthcare industry.

About Ipsos

Ipsos is an independent market research company controlled and managed by research professionals. Founded in France in 1975, Ipsos has grown into a worldwide research group with a strong presence in all key markets. Ipsos ranks third in the global research industry.

With offices in 86 countries, Ipsos delivers insightful expertise across six research specializations: advertising, customer loyalty, marketing, media, public affairs research, and survey management.

Ipsos researchers assess market potential and interpret market trends. They develop and build brands. They help clients build long-term relationships with their customers. They test advertising and study audience responses to various media and they measure public opinion around the globe.

Ipsos has been listed on the Paris Stock Exchange since 1999 and generated global revenues of €1,712,4 million (2 274 M$) in 2013.

Visit www.ipsos.com to learn more about Ipsos’ offerings and capabilities.


Ipsos Healthcare Extends Molecular Diagnostics Portfolio into Japan & Australia

Downloads PDF

Press Release

Contact

Pieter De Richter
Head of Molecular Diagnostics Portfolio
Ipsos Healthcare
+60 3 2297 5628
pieter.derichter@ipsos.com
Joanna Butcher
Marketing and Communications Director, UK
Ipsos Mori
+44 07818 422117
joanna.butcher@ipsos.com